Implantica AG (STU:8IM1) Accounts Receivable : €0.00 Mil (As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Implantica AG Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Implantica AG's accounts receivables for the quarter that ended in . 20 was €0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Implantica AG's Net-Net Working Capital per share for the quarter that ended in . 20 was €N/A.

Implantica AG Accounts Receivable Historical Data

The historical data trend for Implantica AG's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG Accounts Receivable Chart

Implantica AG Annual Data

Trend

Accounts Receivable

Implantica AG Semi-Annual Data

Accounts Receivable

Implantica AG Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Implantica AG Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Implantica AG's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=		/		*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Implantica AG's accounts receivable are only considered to be worth 75% of book value:

Implantica AG's Net-Net Working Capital Per Share for the quarter that ended in . 20 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(	+	0.75 *	+	0.5 *	-	N/A
-		-	)	/	0
=	N/A

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Implantica AG Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Implantica AG's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Implantica AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (STU:8IM1) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

IMP A SDB:Sweden

Address

Aeulestrasse 45, Vaduz, LIE, 9490

Website

https://www.implantica.com

Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. To bring advanced technology into the body, and adequate energy supply is required which would require very large batteries, so, Implantica has developed a wireless energising platform to supply energy to the body through intact skin.

Implantica AG Headlines

No Headlines